The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
COVID-19 Update: Novavax Vaccine for 2024-2025
Download PDF:   US English
Med Lett Drugs Ther. 2024 Sep 23;66(5086):1-2   doi:10.58347/tml.2024.5086a
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the recommendations for use of the 2024-2025 Novavax COVID-19 vaccine.

A 2024-2025 formulation of the Novavax adjuvanted protein subunit COVID-19 vaccine that more closely targets currently circulating SARS-CoV-2 variants is available now under an FDA Emergency Use Authorization (EUA) for use in persons ≥12 years old.1,2 The 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA last month for use in persons ≥12 years old and made available under EUAs for use in persons 6 months to 11 years old.3

THE NEW FORMULATION — The 2024-2025 formulation of the Novavax vaccine contains the spike protein of the JN.1 Omicron strain of SARS-CoV- 2. Currently prevalent "FLiRT" variants (e.g., KP.2, KP.2.3, KP.3, KP.3.1.1, LB.1) are descended from the JN.1 strain.4,5 The Pfizer and Moderna 2024-2025 vaccines code for the spike protein of the KP.2 strain.3

EFFECTIVENESS — As with the mRNA COVID-19 2024-2025 vaccines, no clinical studies evaluating the immunogenicity or effectiveness of the 2024- 2025 Novavax vaccine are available. Authorization of the new formulation was based on the immunogenicity, safety, and efficacy of previous vaccine formulations.1,2

Observational studies suggest that all of the 2023-2024 formulations of the COVID-19 vaccines available in the US were effective in reducing the incidence of COVID-19, but data specific to the Novavax vaccine are limited. In a case-control analysis of 14,860 COVID-19 nucleic acid amplification tests administered at community pharmacies to immunocompetent adults with COVID-like symptoms between September 2023 and May 2024, receipt of any 2023-2024 COVID-19 vaccine at least 7 days before the test was associated with a decreased incidence of SARS-CoV-2 infection. The estimated adjusted vaccine efficacy was 45%; it was 58% for infections likely caused by the XBB.1.5 variant, which the 2023-2024 vaccines targeted, and 37% for infections likely caused by the JN.1 variant.6,7

In similar analyses of tests administered to adults with COVID-like illness within 10 days before or 3 days after an emergency department/urgent care visit (n=245,504) or a hospitalization (n=77,103) between September 2023 and May 2024, receipt of any 2023-2024 COVID-19 vaccine at least 7 days before the test was associated with a decreased incidence of COVID-19 requiring an emergency department/urgent care visit (estimated adjusted vaccine efficacy 36%) or hospitalization (estimated adjusted vaccine efficacy 42%). Among hospitalized immunocompetent persons, the estimated adjusted vaccine efficacy against critical illness was 58%.6,8

ADVERSE EFFECTS — Adverse effects of previous formulations of the Novavax vaccine have included injection-site pain/tenderness, fatigue/malaise, myalgia, arthralgia, headache, nausea, and vomiting. Hypersensitivity reactions, myocarditis, and pericarditis have occurred rarely; the incidence of myocarditis and pericarditis is highest in adolescent and young adult males.9

DOSAGE RECOMMENDATIONS — The 2024-2025 Novavax COVID-19 vaccine is indicated for use in persons ≥12 years old. Generally, persons who have not been vaccinated against COVID-19 previously should receive 2 doses 3-8 weeks apart. Those who have been vaccinated against COVID-19 previously should receive a single 0.5-mL dose ≥2 months after their last COVID-19 vaccine dose. Additional doses, each given ≥8 weeks after the previous dose, can be considered for persons with immunocompromise (solid-organ transplant recipients and equivalent).2,10

CDC RECOMMENDATIONS — The CDC recommends that all persons ≥6 months old be immunized with a 2024-2025 COVID-19 vaccine formulation. Persons ≥12 years old can receive a Pfizer, Moderna, or Novavax vaccine. Persons 6 months to 11 years old should receive a Pfizer or Moderna vaccine.10

REFERENCES

  1. FDA News Release. FDA authorizes updated Novavax COVID-19 vaccine to better protect against currently circulating variants. August 30, 2024. Available at: https://bit.ly/4g8ZpY6. Accessed October 9, 2024.
  2. FDA. Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization of Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula), for individuals 12 years of age and older. August 2024. Available at: https://bit.ly/46M6kBa. Accessed October 9, 2024.
  3. COVID-19 update: New Pfizer and Moderna vaccine formulations for 2024-2025. Med Lett Drugs Ther 2024; 66:151.
  4. COVID-19 Real-Time Learning Network. COVID-19 variant update. September 17, 2024. Available at: https://bit.ly/3XslucR. Accessed October 9, 2024.
  5. CDC. COVID data tracker. Variant proportions. September 14, 2024. Available at: https://bit.ly/3Ka3HhH. Accessed October 9, 2024.
  6. R Link-Gelles. Effectiveness of COVID-19 (2023-2024 formula) vaccines. ACIP Meeting COVID-19 Vaccines. June 27, 2024. Available at: https://bit.ly/4gA1ixl. Accessed October 9, 2024.
  7. R Link-Gelles et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep 2024; 73:77. doi:10.15585/mmwr.mm7304a2
  8. J DeCuir et al. Interim effectiveness of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morb Mortal Wkly Rep 2024; 73:180. doi:10.15585/mmwr.mm7308a5
  9. CDC. Clinical considerations: myocarditis and pericarditis after receipt of COVID-19 vaccines among adolescents and young adults. October 10, 2023. Available at: https://bit.ly/3yXicot. Accessed October 9, 2024.
  10. CDC. Interim clinical considerations for use of COVID-19 vaccines in the United States. September 6, 2024. Available at: https://bit.ly/3KgPdxl. Accessed October 9, 2024.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.